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ABSTRACT 
Objectives. To analyse and describe the clinical and genetic spectrum of Charcot-
Marie-Tooth disease (CMT) caused by mutations in the neurofilament light 
polypeptide gene (NEFL). 
Methods. Combined analysis of new patients with NEFL-related CMT, identified 
from those attending clinics at the participating institutions, and all previously 
reported cases from the literature. 
Results. Five new unrelated patients with CMT carrying heterozygous NEFL 
mutations (N98S, P8R and L311P) were identified. Combined data from these cases 
and 62 kindreds from the literature revealed four common mutations (P8R, P22S, 
N98S and E396K) and three mutational hotspots accounting for 55% and 75% of 
kindreds, respectively. De novo mutations were identified in eight patients. Loss of 
large-myelinated fibres was a uniform feature in 21 sural nerve biopsies, and ‘onion 
bulb’ formations and/or thin myelin sheaths were observed in 67%. The 
neurophysiological phenotype was broad but most patients carrying the mutations 
E90K and N98S had all reported upper limb motor conduction velocities <38 m/s. 
Age of symptoms onset was ≤ 3 years in 25 cases. Pyramidal tract signs were 
described in 13 patients and seven patients were initially diagnosed with or tested 
for inherited ataxia. Patients with E90K and N98S frequently presented before age 3 
years and developed hearing loss or other neurological features including ataxia or 
cerebellar atrophy on brain MRI.  
Conclusions. NEFL-related CMT is clinically and genetically heterogeneous. Based 
on this study, however, we propose mutational hotspots and relevant clinical-genetic 
associations that may be helpful in the evaluation of NEFL sequence variants and 
the differential diagnosis with other forms of CMT. 
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ABBREVIATIONS 
CMAP = compound muscle action potential; CMT = Charcot-Marie-Tooth disease; 
CMT1 = Charcot-Marie-Tooth disease type 1; CMT2 = Charcot-Marie-Tooth disease 
type 2; CK = creatine kinase; ExAC = Exome Aggregation Consortium; MNCV = 
motor nerve conduction velocity; NFL = neurofilament light polypeptide.  
INTRODUCTION 
Charcot-Marie-Tooth disease (CMT) comprises a heterogeneous group of inherited 
neuropathies clinically characterised by progressive, distal-predominant weakness, 
amyotrophy and sensory loss. CMT is classically divided into demyelinating (CMT1) 
and axonal (CMT2) subtypes based on upper limb motor nerve conduction velocities 
(MNCV) below or above 38 m/s, respectively, although intermediate forms of CMT 
with MNCV of 25-45 m/s are also recognised.1,2 Whilst CMT1 is frequently caused 
by mutations affecting peripheral myelin proteins and CMT2 by mutations in genes 
related to neuronal and axonal functions, there is significant genetic overlap 
between CMT subtypes.1,3 
Neurofilaments are neuron-specific intermediate filaments essential for the radial 
growth of axons during development and the maintenance of the axonal diameter.4 
Like other intermediate filaments, neurofilaments are formed by polymerization of 
subunits, the neurofilament light (NFL), medium and heavy polypeptides, all of which 
contain three major domains: globular N-terminal head, α-helical central rod and C-
terminal tail. The rod domain is required for co-assembly between subunits while the 
head and tail domains are involved in regulation of assembly, axonal transport and 
radial growth.4-7  
Mutations in the NEFL gene encoding NFL were first identified as a cause of 
autosomal dominant CMT in 2000,8 and subsequent reports have confirmed the 
association of NEFL mutations with different phenotypes including CMT1 
(designated CMT1F), CMT2 (designated CMT2E), dominant intermediate CMT and 
autosomal recessive CMT.9-18 Despite the growing number of reports about NEFL-
related CMT published in the past 15 years, it is a rare form of inherited neuropathy, 
accounting for less than 1% of all CMT cases in large cohorts,19,20 and obvious 
genotype-phenotype correlations have not been established so far.21 Here we report 
five new patients with NEFL-related CMT and review all previously published cases 
to describe the clinical and genetic spectrum of the disease. 
METHODS 
Patients and clinical investigations 
Patients with diagnosis of NEFL-related CMT were identified from those attending 
neuropathy clinics at the National Hospital for Neurology and Neurosurgery, Queen 
Square, London, UK, and the Department of Neurology, Carver College of Medicine, 
University of Iowa, Iowa, USA. All patients had undergone clinical and 
investigational assessments during the routine diagnostic process and were under 
follow-up at the time of the study. Skeletal muscle strength was manually tested and 
scored according to the Medical Research Council (MRC) grading system ranging 
from 0 (no movement) to 5 (normal strength). The CMT Examination Score, a 
composite subscale of the CMT Neuropathy Score (version 2) based on symptoms 
and signs, with scores ranging from 0 (normal) to 28 (worst score), was obtained in 
four of the patients.22 Laboratory tests, neurophysiological studies, MRI scans and 
nerve and muscle biopsy specimens were performed and analysed according to 
standard procedures. 
Mutation identification 
In four patients, NEFL mutations were identified by bidirectional Sanger sequencing 
during the diagnostic process or as part of a cohort-based study to determine the 
frequency of CMT subtypes. In one patient, a pathogenic NEFL mutation was 
identified through whole-exome sequencing followed by bidirectional Sanger 
sequencing validation. Sanger sequencing of parents’ samples were performed for 
three cases. Further methodological details are provided in appendix e-1 and table 
e-1. 
Additional published cases 
A systematic literature search to identify all previously published cases of NEFL-
related CMT until July 1, 2016 was performed in PubMed using the terms: “NEFL”, 
“neurofilament light”, “neuropathy” and “Charcot-Marie-Tooth”. These cases and the 
patients from our cohort were combined in order to determine the clinical and 
genetic spectrum of NEFL-related CMT. All cases with at least a simple description 
of the phenotype (CMT subtype and familial vs. individual case) were included in the 
analysis of mutation frequencies. Only cases with a diagnosis of CMT and a more 
detailed clinical and neurophysiological description were included in the phenotypic 
analysis. 
Internal whole-exome data 
Whole-exome sequencing data from 202 patients with suspected hereditary CNS 
disorders investigated at the UCL Institute of Neurology, London, UK, was screened 
for non-synonymous NEFL sequence variants with a minor allele frequency ≤1% in 
the 1000 Genomes (http://www.1000genomes.org/) and the Exome Variant Server 
(http://evs.gs.washington.edu/EVS/) datasets. 
Bioinformatic analyses 
NEFL sequence variants are described in accordance with the recommendations of 
the Human Genome Variation Society (http://www.hgvs.org/mutnomen/) using 
GenBank NM_006158.4 as the reference sequence. Minor allele frequencies of all 
NEFL variants were obtained from the Exome Aggregation Consortium (ExAC) 
browser version 0.3 (http://exac.broadinstitute.org) using genomic coordinates from 
the human reference genome assembly 19 (GRCh37). Evolutionary conservation of 
nucleotides was assessed using phyloP (46 vertebrate basewise conservation) and 
GERP scores, which were accessed through the UCSC Genome Browser 
(https://genome.ucsc.edu/cgi-bin/hgGateway) using genomic coordinates from 
GRCh37. Grantham scores were used to assess the physicochemical nature of the 
amino acid substitutions.23 In silico analyses of sequence variants were performed 
using SIFT (http://sift.jcvi.org/), PolyPhen2 (http://genetics.bwh.harvard.edu/pph2/) 
and CADD (http://cadd.gs.washington.edu/). 
Ethics approval 
All human studies were approved by the ethics committee of the National Hospital 
for Neurology and Neurosurgery and UCL Institute of Neurology, London, UK, and 
the Institutional Review Board of the Carver College of Medicine, University of Iowa, 
Iowa, USA. All patients and their relatives provided written informed consent prior to 
genetic testing. 
RESULTS 
Case series 
Five unrelated patients with NEFL-related CMT were identified at the participating 
institutions. Clinical and investigational data is summarised in table 1 and a more 
detailed clinical description is provided in appendix e-1. 
Patients 1, 2 and 3 (figure 1) carried the heterozygous pathogenic mutation N98S. 
All had a similar phenotype consisting of motor developmental delay, hypotonia and 
walking difficulties before age 3-4 years, bilateral hearing loss requiring hearing aids 
between ages 5-8 years, progressive distal greater than proximal motor impairment 
within the first two decades, and marked proprioceptive sensory deficit with positive 
Romberg’s test and gait ataxia. Patients 1 and 2, who had the longest follow-up, 
also developed proximal lower limb weakness and scapular winging, appendicular 
ataxia, and cerebellar features supported by neuro-otological examination or brain 
MRI (figure 2). Additional features included tongue hemiatrophy in patient 1, mild 
cervical spinal cord volume loss in patients 1 and 2, and optic nerve hypoplasia in 
patient 3. Neurophysiological studies were consistent with a length-dependent motor 
and sensory neuropathy with reduced or absent compound muscle action potential 
(CMAP) amplitudes and upper limb MNCV ranging from 23 to 35 m/s 
(corresponding CMAPs 1.5 mV 0.8 mV; table e-2). In patients 1 and 2, ulnar nerve 
CMAP waveforms were dispersed or complex on proximal stimulation. Co-
segregation analyses indicated that the heterozygous mutation N98S occurred de 
novo in the three probands. Biological paternity was confirmed by short-tandem 
repeat analysis for patients 1 and 2 (results not shown; patient 3 was not tested). 
Patient 4 carried the heterozygous pathogenic mutation P8R. He developed 
progressive distal motor and sensory impairment from the second decade along with 
restless legs syndrome and periodic limb movements disorder. Neurophysiological 
studies in his 40s revealed a length-dependent motor and sensory neuropathy with 
reduced or absent CMAP amplitudes and upper limb MNCV ranging from 31 to 44 
m/s (corresponding CMAPs 1.7 mV; table e-2). 
Patient 5 carried the novel heterozygous mutation L311P. He presented in the sixth 
decade with hand tremor followed with gait ataxia and muscle weakness and 
atrophy in the lower limbs. Neurophysiological studies confirmed a length-dependent 
motor and sensory neuropathy with reduced CMAP amplitudes in the lower limbs, 
upper limb MNCV ranging from 43 to 55 m/s (corresponding CMAPs 6.6 and 5.4 
mV), and dispersion of CMAP waveforms in two nerve segments (table e-2). 
Sural nerve biopsies from patients 2 and 4 at ages 24 and 46, respectively, showed 
severe reduction in myelinated fibre density with a nearly  complete absence of 
large myelinated fibres (figure 3A and B). Immunostaining for neurofilament proteins 
showed reduced density of axons, mainly of large axonscaliber. There was no 
evidence of active axonal degeneration. Definite Occasional regeneration clusters 
were observed in patient 4. Both biopsies contained irregularly-shaped fibres. 
Disproportionately thin myelin sheaths and onion bulbs, confirmed by electron 
microscopy imaging, were seen in patient 2 (figure 3C) but not in patient 4 (figure 
3D). 
Literature review 
A systematic review of the literature revealed published data on 62 kindreds with 
NEFL-related CMT.8-18,24-48 These cases and the five unrelated patients from our 
cohort were combined for analysis. 
Mutational spectrum 
A total of 30 different NEFL mutations have been reported to date (tables 2 and e-
3).8-18,24-48 For descriptive reasons, the mutations c.22_23delCCinsAG and c.23C>G, 
causing the same amino acid substitution (P8R), were classified as one single 
mutation. For two mutations (E186* and Q334P) there was no clinical data available. 
R421* has been reported in a family with an overlapping myopathic-neurogenic 
phenotype40 and also in association with CMT41 but no clinical details were available 
for the latter. 
Of the remainder 27 mutations, 17 were private to a single kindred and 10 were 
observed in two or more kindreds. Twenty-four mutations were clustered in six 
regions of the NFL polypeptide (figure 4): the initial segment of the head domain 
(amino acid positions 8-22), the junction between the head and the rod domains (90-
98), coil 2A (265-268), the mid portion of coil 2B (311-336), the end portion of coil 
2B (384-396), and the tail subdomain A (421-440). Mutations in the head domain 
and the two ends of the rod domain accounted for 75% of kindreds and four 
common mutations within these regions (P8R, P22S, N98S, and E396K) were 
observed in 55% of kindreds. Only three mutations (E140*, A149v, and E210*) were 
located in coil 1B. No mutations were observed in linker regions of the rod domain or 
the tail subdomain B. 
A detailed analysis of all mutations, including conservation and pathogenicity 
prediction scores, is provided in table e-3. Pathogenicity for 23 of the 30 mutations 
was supported by co-segregation studies, existence of other mutations in the same 
amino acid position, detection in more than one kindred or functional studies (in vitro 
or animal models). This information was not available for the remaining seven 
mutations (E186*, L311P, L333P, Q334P, L336P, F439I and R421*); of these, only 
F439I is described in the EXaC dataset, being present in 13 alleles (minor allele 
frequency of 0.01%). 
Inheritance pattern 
Of the 67 kindreds with NEFL mutations, 27 correspond to individual cases and 40 
correspond to families or familial cases. Of the latter, 29 had an autosomal dominant 
inheritance based on co-segregation analysis. This was not reported or was not 
available in nine additional families with probable autosomal dominant inheritance; 
only two of them, however, had private mutations (L311P reported in this study and 
P8Q). The inheritance pattern was autosomal recessive in two consanguineous 
families in which all affected individuals had homozygous nonsense mutations 
located in coil 1B (E140* and E210*).13,14 
Of the 27 individual cases analysed, one was adopted and 26 were reported as 
isolated or sporadic. Eight of these patients had de novo mutations based on co-
segregation analysis. Of note, 11 out of 15 patients with substitutions of amino acids 
E90 and N98 (E90K and N98S/T) were isolated/sporadic and six of them had 
confirmed de novo mutations.10,14  
Neurophysiologic pattern 
A neurophysiologic classification of the peripheral neuropathy was reported for 58 
individual cases or families with the following distribution: CMT1 or demyelinating 
neuropathy in 18 kindreds (31%), CMT2 or axonal neuropathy in 23 kindreds (40%), 
and intermediate CMT or neuropathy with axonal and demyelinating features in 17 
kindreds (29%).8,9,11-18,24-34,36,37,39,42,43,45,46,48  
Upper limb nerve conduction data was available for 115 patients from 53 kindreds: 
44 patients (38%) had all reported upper limb MNCV ≥38 m/s, 24 patients (21%) 
had upper limb MNCV ranging from <38 and ≥38 m/s, and 47 patients (41%) had all 
reported upper limb MNCV <38 m/s.10,11,13-18,24,25,27-33,35,36,38,39,46,47 Upper limb CMAP 
values were available in 21 patients from the latter group, of whom 18 had 
amplitudes ≥75% of lower limit of normal. 
Analysis of the same upper limb MNCV data using 25 m/s and 45 m/s as cut-off 
values revealed that 12 patients (10%) had all reported values >45 m/s, 74 patients 
(64%) had all reported values between 25-45 m/s, and 9 patients (8%) had all 
reported values <25 m/s; the remaining 20 patients had upper limb MNCV in 
overlapping ranges. 
Median and/or ulnar MNCV <20 m/s were detected in eight patients, five of them 
with recessive mutations (E140* and E210*) and three with dominant mutations 
(P8L, E90K and N98S).10,13,14,18 Of the four common NEFL mutations, only N98S 
was consistently associated with upper limb MNCV <38 m/s although MNCV in 
proximal nerve segments varied between 30.1 and 47.8 m/s in one kindred 
(classified as dominant intermediate-CMT).10,14,18,25,35,47 
Sural nerve histopathology 
Twenty-one sural nerve biopsies of patients with NEFL-related CMT, including two 
from our cohort, have been reported to date (table 3)10,11,13,14,16,26,28,29,32,34,39. Loss of 
large myelinated features was a uniform feature. Onion bulbs and thin or irregularly-
folded myelin sheaths were observed in 14 biopsies (67%) and giant axons, with or 
without thin myelin sheaths, were found in six (29%). 
Phenotype-genotype associations 
To date, a total of 173 individuals with NEFL-related CMT have been reported as 
clinically examined.8-18,24,25,28-39,45-47 The majority developed a classical CMT 
phenotype but some of them had atypical features including hearing loss, tremor, 
cerebellar features, and pyramidal tract signs (tables 3 and 4). 
Early onset with delayed motor milestones. Twenty-five patients from 18 kindred had 
onset of symptoms at or before age 3 years.10,13,14,18,32,35,36,38,39,47 Of them, 18 
patients were reported as having delayed walking or motor milestones with or 
without additional features such as hearing loss (11 patients), hypotonia (8 patients), 
intellectual impairment (3 patients), growth retardation (1 patient), or optic nerve 
hypoplasia (1 patient). Four dominant and one recessive mutation were associated 
with both early-onset and motor delay (P8L, E90K, N98S, E210* and E396K). With 
one exception, all patients with substitutions of amino acids E90 and N98 (E90K and 
N98S/T) had onset at age ≤3 years.  
Pyramidal tract signs. A variable combination of brisk reflexes, extensor plantar 
responses and lower limb spasticity (sometimes simply described as upper motor 
neuron involvement), with or without evidence of prolonged central motor conduction 
times, has been observed in 13 patients from 7 kindreds.14,16,17,31,38,45 Except for the 
mutation Y265C, all mutations associated with pyramidal tract signs were located in 
end portion of the rod domain (Y389C and E396K) and the tail subdomain A (F439I 
and P440L). 
Cerebellar features. Limb or gait ataxia (sensory, cerebellar, episodic or described 
as gait ataxia or wide-based gait) was reported in 22 patients but distinction 
between sensory or cerebellar ataxia based on the available data was not always 
possible.11,14-18,28-30 Seven patients carrying the mutations P8R, N98S, L311P, 
C322_N326del and E396K were initially diagnosed with or tested genetically for 
spinocerebellar ataxia or Friedreich’s ataxia, four of them with dysarthria and/or 
nystagmus. Cerebellar atrophy on brain MRI was observed in 4 patients with the 
mutations N98S and E396K (table 3).14,18,47 
Raised creatine kinase (CK) levels and proximal weakness. Raised CK levels up to 
1414 IU/L have been detected in 14 patients carrying the mutations N98S, Q332P 
and E396K.17,37,39 Of these patients, six had an element of proximal weakness in the 
upper or lower limbs or a waddling gait. This gait pattern is also described in 
patients with early-onset disease due to N98S and E396K.14 Myopathic features on 
EMG or muscle biopsy, however, have only been reported in two individuals with the 
E396K mutation and in one family with a myopathic-neurogenic phenotype carrying 
the mutation R421*.39,40  
Screening for additional mutations 
Based on the observation that patients with NEFL mutations may develop CNS 
features, we retrospectively reviewed whole-exome sequencing data from patients 
with pure or complicated hereditary spastic paraplegia (27 cases), early-onset ataxia 
(100 cases), and complex CNS syndromes (75 cases with a variable combination of 
ataxia, spasticity, epilepsy, extrapyramidal features and cognitive involvement), 
searching for rare or novel NEFL variants. Two heterozygous missense NEFL 
variants were identified: Q537R (c.1610A>G, rs377121179) and L336V 
(c.1006C>G, rs551896980). Both variants are present in population databases 
(minor allele frequency of 0.03% and 0.02%, respectively, in the EXaC dataset) and 
predicted to be tolerated or benign by SIFT and PolyPhen2. No other rare variants in 
NEFL were found. 
DISCUSSION 
In this study, we have reported five new cases of NEFL-related CMT and performed 
an analysis of the entire genetic and clinical spectrum of the disease based on data 
from the literature. 
We observed that NEFL mutations are clustered in terms of frequency and location 
in six regions of the NFL protein, predominantly in the initial segment of the head 
domain, the junction between the head and rod domains and the end portion of the 
rod domain. The pathogenic relevance of these three regions is also supported by in 
vitro and animal studies. Substitution of amino acids P8 and P22 of NFL disrupts its 
ability to self-assemble into a filamentous network,49-52 affects the axonal transport 
of neurofilaments and mitochondria51,53,54 and impairs motor neuron viability in 
vitro.55 Transient transfection studies also indicate that T21Afs*83, E90K and N98S 
result in NFL assembly defects.12,50 In addition, mice models of the mutations N98S 
and E396K, located at the two ends of the rod domain, display an abnormal hindlimb 
posture together with muscle atrophy and reduced MNCV in the hNFLE396K mice and 
tremor in the NeflN98S/+ mice.56,57 
Mutations affecting three other regions of NFL (coil 2A, mid portion of coil 2B and tail 
subdomain A) were less common. Six mutations involved the mid region of coil 2B, 
including Q332P, which has been detected in two families and causes similar 
defects in neurofilament assembly and transport as P8R in vitro.49,51,53 For four 
mutations located in this region (L333P, Q334P, L336P and L311P reported in this 
study), however, there was no co-segregation or functional data available. Three 
mutations were located in the tail subdomain A but co-segregation data was not 
reported for the family with CMT and R421* or for F439I, which has a minor allele 
frequency of 0.01%. Therefore, further research is needed to determine if these 
regions of NFL are mutational hotspots. 
NEFL-related CMT presented with a broad clinical and neurophysiological 
phenotype. The mode of transmission was usually autosomal dominant although 
40% of kindreds in our study were classified as sporadic or isolated cases and de 
novo mutations were confirmed in eight of them. Disease onset varied between the 
first and sixth decades of life, with 13% of patients having an early-onset 
presentation (≤3 years) often associated with delayed walking or motor milestones. 
Neurophysiologically, NEFL-related CMT was reported as axonal, demyelinating or 
mixed/intermediate in 40%, 31% and 29% of kindreds, respectively; descriptions 
were not uniform across the literature, but our analysis of published data also 
suggests that neuropathies with MNCV in the demyelinating or intermediate ranges 
are overall more frequent than those with upper limb MNCV >38 m/s. Although the 
reduced velocities may well be mainly explained by preferential loss of large-
myelinated fibres confirmed in 21 sural nerve biopsies, additional features 
suggestive of demyelination and remyelination (onion bulbs and/or thin myelin 
sheaths) were observed in 67% of them. 
Establishing definite genotype-phenotype correlations in patients with NEFL-related 
neuropathies is difficult given the significant number of private mutations and low 
prevalence of the disease. Pyramidal tract signs might be preferentially associated 
with mutations located towards the end of the NFL protein (end of rod domain and 
tail subdomain A) but this should be confirmed in future studies. Ataxia was 
described in association with the four common mutations (P8R, P22S, N98S and 
E396K) and raised CK levels was more frequently described in association with the 
mutation E396K. 
We identified, however, an important clinical association with the mutations E90K 
and N98S (n = 14). Most patients with these mutations were isolated or sporadic 
(71%), six with confirmed de novo mutations (three from our cohort); presented 
before age 3 (93%) with delayed walking or motor milestones (86%); had all 
reported upper limb MNCV in the demyelinating range (86%); and developed 
additional features such as hearing loss (64%), ataxia with or without nystagmus or 
dysarthria (36%), hypotonia (29%) and less frequently intellectual impairment, 
tongue hemiatrophy, signs of vestibular dysfunction and optic nerve hypoplasia; 
cerebellar atrophy on brain MRI was confirmed in three cases. Patients carrying 
E90K and N98S, therefore, presented with a rather uniform syndrome for which we 
propose the acronym “DECADE” (demyelinating neuropathy based on distal upper 
limb MNCV with cerebellar signs and/or ataxia, deafness and delayed motor 
milestones), which also highlights the early onset of the disease. Although only six 
out of 14 patients conformed to the full syndrome, its recognition may aid in the 
differential diagnosis with other autosomal recessive cerebellar ataxias.18 Of note, 
NFL E90K or N98S mutants share a particular phenotype in vitro, different from that 
observed with substitutions of amino acid P8,50 and NeflN98S/+ mice display an early-
onset phenotype with tremor and pathological changes in the CNS including 
neurofilament aggregates in the spinal cord and cerebellum.56 
Beyond the above genotype-phenotype associations, identification of uncommon 
clinical features such as hearing loss, pyramidal tract signs or ataxia may be useful 
in the differential diagnosis of NEFL-related CMT with other forms of CMT. In our 
cohort of 202 patients with CNS syndromes we found no other potential NEFL 
mutations, which supports that these are unlikely to present with a predominantly 
CNS phenotype. 
We acknowledge this study’s limitations related to the amount, completeness and 
heterogeneity of the data in the literature. Missing data may indeed reflect true 
negative data (i.e., absence of a clinical feature), false negative data due to lack of 
assessment or unreported data. Also, cases with atypical clinical characteristics may 
be overrepresented in the literature because of their particular interest. We believe, 
however, that the results of the present study may be helpful in the evaluation of 
novel NEFL sequence variants and the differential diagnosis with other CMT 
subtypes. Also, our study highlights potential aspects of interest to be evaluated in 
future studies. 
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FIGURE LEGENDS 
Figure 1. Family trees of patients from our series. The number corresponds to 
the patient number in the text and table 1. 
Figure 2. Brain MRI. Cranial sagittal T1-weighted MR images showing mild 
cerebellar and medullary volume loss in patient 1 (P1) but not in patients 2 (P2), 4 
(P4) and 5 (P5). Mild volume loss of cervical spinal cord can also be appreciated in 
patients P1 and P2. 
Figure 3. Morphological appearances of sural nerve biopsies from patients 2 
(A and C) and 4 (B and D). Semi-thin resin preparations stained with toluidine blue 
(A) and methylene blue azure–basic fuchsin (B) show transverse sections of nerve 
fascicles in both of which there iswith severe widespread loss of large myelinated 
fibres (yellow arrows indicate occasional remaining large fibres). In both patients the 
small myelinated fibres are better preserved and several regeneration clusters are 
evident in case 2 (B, green arrow). Ultrastructural examination of the biopsy from the 
first patient (C) shows a thinly myelinated fibre with thin myelin sheath (red arrow) 
surrounded by several layers of Schwann cell profiles (blue arrow) closely 
resembling anconsistent with an onion bulb, while electron microscopy in the other 
patient (D) confirms marked reduction of large myelinated fibres accompanied by 
endoneural fibrosis but shows no onion bulb formations. Scale bar: 30μm in A and 
B; 3μm in C and D. 
Figure 4. Localization of reported NEFL mutations in the neurofilament light 
polypeptide. The size of the NEFL gene (cDNA; top line) and neurofilament light 
polypeptide (figure and bottom line) correspond to the number of bases and amino 
acids involved; numbers in the top line indicate base and numbers in the bottom line 
indicate amino acid position. Light blue = linker regions of the rod domain. Light grey 
= mutations for which there was no clinical information available. AD = autosomal 
dominant; AR = autosomal recessive; C1A, C1B, C2A and C2B = coil 1A, 1B, 2A 
and 2C subdomains; SA and SB = subdomains A and B. 
